Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + Erlotinib vs Erlotinib in Advanced NSCLC
NCT00130728Phase 3Completed
- Sponsor
- Genentech
- Start
- Jun 2005
- Primary completion
- Jul 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Genentech. Started Jun 2005; status: completed.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00130728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00130728.